mRNA Vaccines And Therapeutics Market, By Treatment Type (Cell Therapy, Gene Therapy, and Monoclonal Antibody) , By Type , By Application, By End User, By Country, and By Region Global Industry Analysis, Market Size, Market Share & Forecast from 2026-2033
|
Report ID
AV4893
|
Published Date
March 2026
|
Pages
339
|
Industry
Healthcare
|
|
|
Base Year
2025
|
Historical Data
2019-2024
|
Delivery Timeline
24 Hour
|
EPORT HIGHLIGHT
mRNA Vaccines And Therapeutics Market size was valued at US$2,980.76 Million in 2025, expanding at a CAGR of 30.6% from 2026 to 2033.
mRNA Vaccines and Therapeutics are a class of advanced biotechnology solutions that use messenger RNA (mRNA) to instruct cells to produce specific proteins for disease prevention or treatment. This approach enables the immune system to recognize and respond to targeted pathogens or abnormal cells. mRNA-based platforms deliver genetic instructions that trigger controlled protein production, supporting the development of vaccines and therapeutic applications for infectious diseases, cancer, and other medical conditions. These solutions offer significant advantages, including rapid development, precise targeting, and flexible design. By enhancing immune responses and enabling faster innovation, mRNA vaccines and therapeutics are driving the advancement of modern medicine and shaping next-generation healthcare treatments. The World Health Organization’s mRNA Technology Transfer Programme, integrated into its Health Technology Access Programme (HTAP), is expanding regional capacity for mRNA vaccine and therapeutic development by partnering with manufacturers and regulators across multiple continents.
mRNA Vaccines And Therapeutics Market- Market Dynamics
Rising Prevalence of Chronic Diseases
The increasing prevalence of chronic diseases refers to the growing number of individuals affected by long-term medical conditions such as cancer, cardiovascular diseases, diabetes, and autoimmune disorders worldwide. This trend is driven by factors including aging populations, lifestyle changes, and environmental influences, placing greater pressure on healthcare systems. In the context of mRNA vaccines and therapeutics, the rising burden of chronic diseases is driving the development of innovative treatment approaches that leverage mRNA technology to target specific disease pathways. mRNA platforms enable personalized and targeted therapies, and the growing incidence of chronic conditions is accelerating research and investment in advanced biotechnology solutions. The prevalence of chronic diseases is thus a key factor strengthening the demand for mRNA-based therapeutics in modern healthcare.
For example, in November 2025, the Organisation for Economic Co-operation and Development (OECD) reported that chronic conditions—including cardiovascular diseases, cancer, respiratory diseases, and diabetes—remain major health burdens across OECD countries. The report highlighted that approximately 8.6% of adults were living with diabetes in 2022, and over one-third of people aged 16 and above reported having a long-standing illness. Among primary care users aged 45 and older in 2024, 82% had at least one chronic condition, and 52% experienced two or more conditions, underscoring the growing prevalence of chronic diseases and the increasing need for effective long-term healthcare management.
mRNA Vaccines And Therapeutics Market- Segmentation Analysis:
The Global mRNA Vaccines And Therapeutics Market is segmented on the basis of Treatment Type, Type, Application, End User, and Region.
The mRNA Vaccines and Therapeutics market is segmented based on treatment type into monoclonal antibodies, gene therapy, and cell therapy. The monoclonal antibody segment represents a significant share of the market due to its effectiveness in targeted disease treatment. Targeted treatments are designed to specifically identify and act on particular cells, proteins, or pathways associated with a disease, enhancing treatment precision, improving clinical outcomes, and minimizing damage to healthy cells. In the context of mRNA vaccines and therapeutics, monoclonal antibodies are widely applied in immune-based therapies for conditions such as cancer, infectious diseases, and autoimmune disorders. These treatments help neutralize harmful pathogens, block disease-causing mechanisms, and strengthen immune responses, enabling more advanced and effective therapeutic solutions. For example, in February 2025, the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) reported that biologic medicines, including monoclonal antibodies, already benefit over 350 million patients globally for the treatment of diseases such as cancer, diabetes, and rare disorders. The report also highlighted the ongoing expansion of pharmaceutical innovation, with 69 novel active substances launched globally in 2023 and over 12,700 medicines in various phases of clinical development as of October 2024, reflecting strong growth in advanced biologic and antibody-based therapies.
The market is also segmented based on vaccine type into self-amplifying mRNA-based vaccines and conventional non-amplifying mRNA-based vaccines. The self-amplifying mRNA (sa-mRNA) vaccines segment accounts for a substantial portion of the market due to its enhanced protein expression and dose-sparing potential. Enhanced protein expression refers to the ability of sa-mRNA vaccines to replicate within cells, producing higher levels of antigen and eliciting stronger immune responses. This increased expression allows for broader immune coverage, potentially fewer booster doses, and a faster response to emerging pathogens. Self-amplifying mRNA vaccines are highly attractive for applications in infectious diseases, oncology, and personalized therapeutics, supporting the rapid growth and adoption of mRNA vaccine technologies worldwide. For instance, in January 2026, the UK Medicines and Healthcare Products Regulatory Agency (MHRA) approved Zapomeran (Kostaive), a self-amplifying mRNA COVID-19 vaccine for adults aged 18 years and older. This approval marked one of the first regulatory authorizations of an sa-mRNA vaccine, reflecting a shift toward next-generation mRNA technology in public health. The vaccine is administered as a single 0.5mL booster dose, containing self-amplifying mRNA designed to produce the SARS-CoV-2 spike protein and enhance immunity against COVID-19.
mRNA Vaccines And Therapeutics Market- Geographical Insights
The mRNA Vaccines and Therapeutics market shows significant regional variation, influenced by differences in healthcare infrastructure, R&D investment, and technology adoption. North America is experiencing strong growth, with increasing adoption of mRNA-based therapies, a robust pipeline of clinical trials, and a growing focus on personalized medicine, particularly in the U.S. and Canada. Europe is witnessing steady expansion, driven by rising investments in biotechnology, supportive regulatory frameworks, and the adoption of innovative vaccine and therapeutic platforms.
The Asia Pacific region is rapidly expanding, fueled by improving healthcare access, large patient populations, increasing government support, and the development of local biotechnology capabilities in countries such as China, India, Japan, and South Korea. In comparison, Latin America, the Middle East, and Africa are gradually developing their market presence, supported by enhanced healthcare infrastructure, growing awareness of mRNA therapeutics, and increased participation in clinical research and vaccine programs. For instance, governmentbacked investments such as the UK’s £1billion BioNTech commitment, supported in part by up to £129million in government funding, are establishing new research and production hubs for mRNAbased medicines and creating highly skilled jobs, demonstrating policymakers’ prioritization of life sciences and biotechnology innovation.
Japan mRNA Vaccines And Therapeutics Market – Country Insights
The Japan mRNA Vaccines and Therapeutics market is experiencing steady growth, driven by a well-established healthcare infrastructure and the rapid adoption of biotechnology innovations. Healthcare providers and research institutions are increasingly utilizing mRNA vaccines and therapeutics for infectious disease prevention and to support personalized medicine initiatives. Strong participation from leading domestic and global pharmaceutical companies, combined with supportive government policies for vaccine development, approval, and deployment, continues to foster market expansion.
Additionally, growing emphasis on improving public health outcomes and advancing immunization programs is further accelerating adoption across healthcare and research settings in Japan. For example, in 2025, the Commonwealth Fund reported that Japan’s statutory health insurance system covers approximately 98.3% of the population, ensuring near-universal access to hospital care, primary and specialty services, and prescription medications under mandatory residence- and employment-based plans. The national government establishes the health insurance fee schedule and provides subsidies to local governments and insurers to maintain quality and affordability. Out-of-pocket maximums range from JPY 340,000 to 2.12 million annually (USD 3,400–21,200), depending on age and income, illustrating strong and sustained government support for comprehensive healthcare coverage and financial protection.
mRNA Vaccines And Therapeutics Market- Competitive Landscape:
The mRNA Vaccines and Therapeutics market is moderately concentrated, with several leading biotechnology and pharmaceutical companies shaping the competitive landscape. Key players include Pfizer Inc., Moderna, Inc., BioNTech SE, GlaxoSmithKline, Daiichi Sankyo, CureVac N.V., AstraZeneca, Ethris, Sanofi, Arcturus Therapeutics, Innovac Therapeutics, Kernal Biologics, Pantherna Therapeutics, pHion Therapeutics, Recode Therapeutics, Rejuvenation Technologies, RNAimmune, Strand Therapeutics, Walvax, and Ziphius Vaccines. These companies compete by developing innovative mRNA-based vaccines and therapeutics for infectious diseases, oncology, and personalized medicine, focusing on enhanced efficacy, safety, and rapid adaptability.
For example, in 2024, Moderna, Inc. advanced its mRNA vaccine platform by incorporating self-amplifying mRNA technology, enabling higher protein expression, stronger immune responses, and faster adaptation to emerging pathogens. Market growth is driven by increasing demand for effective, rapid-response vaccines and therapeutics, particularly in the context of emerging infectious diseases and cancer immunotherapy. Companies are also expanding capabilities through enhanced delivery systems, multi-dose formulations, predictive immunogenicity modeling, and scalable manufacturing platforms to meet the evolving needs of healthcare systems and the growing preference for innovative, accessible, and safe mRNA-based treatments.
Recent Developments:
- In 2025, Pfizer Inc. announced a collaboration with a leading biotechnology partner to develop next-generation mRNA vaccines aimed at improving immune response, expanding protection against emerging infectious diseases, and enhancing vaccine delivery efficiency. The initiative leverages self-amplifying mRNA technology and advanced delivery platforms, positioning Pfizer as a leader in innovative mRNA therapeutics and potentially establishing new standards in vaccine innovation.
- In 2024, Kernal Biologics initiated a joint project with a prominent research institute to develop advanced mRNA therapeutics for oncology and personalized medicine. The collaboration focuses on optimizing mRNA design, delivery systems, and immunogenicity to improve patient outcomes. By integrating scalable manufacturing processes and predictive modeling, Kernal Biologics aims to strengthen its position as a key innovator in next-generation mRNA-based therapies.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL MRNA VACCINES AND THERAPEUTICS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- AstraZeneca
- Arcturus Therapeutics
- BioNTech SE
- CureVac N.V.
- Daiichi Sankyo
- Ethris
- GlaxoSmithKline
- Innovac Therapeutics
- Kernal Biologics
- Pantherna Therapeutics
- pHion Therapeutics
- Pfizer Inc.
- Recode Therapeutics
- Rejuvenation Technologies
- RNAimmune
- Strand Therapeutics
- Moderna, Inc.
- Walvax
- Ziphius Vaccines
- Others
GLOBALMRNA VACCINES AND THERAPEUTICS MARKET, BY TREATMENT TYPE - MARKET ANALYSIS, 2020 - 2033
- Cell Therapy
- Gene Therapy
- Monoclonal Antibody
- Other
GLOBAL MRNA VACCINES AND THERAPEUTICS MARKET, BY TYPE - MARKET ANALYSIS, 2020 - 2033
- Conventional Non-Amplifying mRNA-Based Vaccines
- Self-Amplifying mRNA-based Vaccines
GLOBAL MRNA VACCINES AND THERAPEUTICS MARKET, BY APPLICATION- MARKET ANALYSIS, 2020 - 2033
- Autoimmune Diseases
- Cancer
- Infectious Diseases
- Others
GLOBAL MRNA VACCINES AND THERAPEUTICS MARKET, BY END USER- MARKET ANALYSIS, 2020 - 2033
- Clinics
- Hospitals
- Research Laboratories and Organizations
- Others
GLOBAL MRNA VACCINES AND THERAPEUTICS MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
TABLE OF CONTENT
1. mRNA Vaccines And Therapeutics Market Overview
1.1. Study Scope
1.2. Market Estimation Years
2. Executive Summary
2.1. Market Snippet
2.1.1. mRNA Vaccines And Therapeutics Market Snippet by Treatment Type
2.1.2. mRNA Vaccines And Therapeutics Market Snippet by Type
2.1.3. mRNA Vaccines And Therapeutics Market Snippet by Application
2.1.4. mRNA Vaccines And Therapeutics Market Snippet by End User
2.1.5. mRNA Vaccines And Therapeutics Market Snippet by Country
2.1.6. mRNA Vaccines And Therapeutics Market Snippet by Region
2.2. Competitive Insights
3. mRNA Vaccines And Therapeutics Key Market Trends
3.1. mRNA Vaccines And Therapeutics Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. mRNA Vaccines And Therapeutics Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. mRNA Vaccines And Therapeutics Market Opportunities
3.4. mRNA Vaccines And Therapeutics Market Future Trends
4. mRNA Vaccines And Therapeutics Industry Study
4.1. PEST Analysis
4.2. Porter’s Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. mRNA Vaccines And Therapeutics Market: Impact of Escalating Geopolitical Tensions
5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts
6. mRNA Vaccines And Therapeutics Market Landscape
6.1. mRNA Vaccines And Therapeutics Market Share Analysis, 2025
6.2. Breakdown Data, by Key Manufacturer
6.2.1. Established Players’ Analysis
6.2.2. Emerging Players’ Analysis
7. mRNA Vaccines And Therapeutics Market – By Treatment Type
7.1. Overview
7.1.1. Segment Share Analysis, By Treatment Type, 2025&2033 (%)
7.1.2. Cell Therapy
7.1.3. Gene Therapy
7.1.4. Monoclonal Antibody
7.1.5. Other
8. mRNA Vaccines And Therapeutics Market – By Type
8.1. Overview
8.1.1. Segment Share Analysis, By Type, 2025&2033 (%)
8.1.2. Conventional Non-Amplifying mRNA-Based Vaccines
8.1.3. Self-Amplifying mRNA-based Vaccines
9. mRNA Vaccines And Therapeutics Market – By Application
9.1. Overview
9.1.1. Segment Share Analysis, By Application, 2025&2033 (%)
9.1.2. Autoimmune Diseases
9.1.3. Cancer
9.1.4. Infectious Diseases
9.1.5. Others
10. mRNA Vaccines And Therapeutics Market – By End User
10.1. Overview
10.1.1. Segment Share Analysis, By Type, 2025&2033 (%)
10.1.2. Clinics
10.1.3. Hospitals
10.1.4. Research Laboratories and Organizations
10.1.5. Others
11. mRNA Vaccines And Therapeutics Market– By Geography
11.1. Introduction
11.1.1. Segment Share Analysis, By Geography, 2025&2033 (%)
11.2. North America
11.2.1. Overview
11.2.2. mRNA Vaccines And Therapeutics Key Manufacturers in North America
11.2.3. North America Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
11.2.4. North America Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
11.2.5. North America Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.2.6. North America Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.2.7. North America Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.2.8. U.S.
11.2.8.1. Overview
11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.2.8.3. U.S. Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
11.2.8.4. U.S. Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.2.8.5. U.S. Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.2.8.6. U.S. Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.2.9. Canada
11.2.9.1. Overview
11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.2.9.3. Canada Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
11.2.9.4. Canada Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.2.9.5. Canada Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.2.9.6. Canada Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.3. Europe
11.3.1. Overview
11.3.2. mRNA Vaccines And Therapeutics Key Manufacturers in Europe
11.3.3. Europe Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
11.3.4. Europe Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
11.3.5. Europe Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.3.6. Europe Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.3.7. Europe Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.3.8. Germany
11.3.8.1. Overview
11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.8.3. Germany Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
11.3.8.4. Germany Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.3.8.5. Germany Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.3.8.6. Germany Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.3.9. UK
11.3.9.1. Overview
11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.9.3. UK Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
11.3.9.4. UK Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.3.9.5. UK Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.3.9.6. UK Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.3.10. France
11.3.10.1. Overview
11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.10.3. France Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
11.3.10.4. France Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.3.10.5. France Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.3.10.6. France Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.3.11. Italy
11.3.11.1. Overview
11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.11.3. Italy Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
11.3.11.4. Italy Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.3.11.5. Italy Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.3.11.6. Italy Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.3.12. Spain
11.3.12.1. Overview
11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.12.3. Spain Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
11.3.12.4. Spain Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.3.12.5. Spain Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.3.12.6. Spain Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.3.13. The Netherlands
11.3.13.1. Overview
11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.13.3. The Netherlands Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
11.3.13.4. The Netherlands Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.3.13.5. The Netherlands Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.3.13.6. The Netherlands Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.3.14. Sweden
11.3.14.1. Overview
11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.14.3. Sweden Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
11.3.14.4. Sweden Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.3.14.5. Sweden Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.3.14.6. Sweden Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.3.15. Russia
11.3.15.1. Overview
11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.15.3. Russia Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
11.3.15.4. Russia Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.3.15.5. Russia Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.3.15.6. Russia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.3.16. Poland
11.3.16.1. Overview
11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.16.3. Poland Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
11.3.16.4. Poland Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.3.16.5. Poland Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.3.16.6. Poland Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.3.17. Rest of Europe
11.3.17.1. Overview
11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.17.3. Rest of the Europe Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
11.3.17.4. Rest of the Europe Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.3.17.5. Rest of the Europe Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.3.17.6. Rest of the Europe Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.4. Asia Pacific (APAC)
11.4.1. Overview
11.4.2. mRNA Vaccines And Therapeutics Key Manufacturers in Asia Pacific
11.4.3. APAC Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
11.4.4. APAC Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
11.4.5. APAC Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.4.6. APAC Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.4.7. APAC Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.4.8. China
11.4.8.1. Overview
11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.8.3. China Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
11.4.8.4. China Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.4.8.5. China Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.4.8.6. China Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.4.9. India
11.4.9.1. Overview
11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.9.3. India Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
11.4.9.4. India Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.4.9.5. India Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.4.9.6. India Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.4.10. Japan
11.4.10.1. Overview
11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.10.3. Japan Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
11.4.10.4. Japan Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.4.10.5. Japan Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.4.10.6. Japan Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.4.11. South Korea
11.4.11.1. Overview
11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.11.3. South Korea Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
11.4.11.4. South Korea Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.4.11.5. South Korea Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.4.11.6. South Korea Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.4.12. Australia
11.4.12.1. Overview
11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.12.3. Australia Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
11.4.12.4. Australia Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.4.12.5. Australia Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.4.12.6. Australia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.4.13. Indonesia
11.4.13.1. Overview
11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.13.3. Indonesia Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
11.4.13.4. Indonesia Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.4.13.5. Indonesia Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.4.13.6. Indonesia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.4.14. Thailand
11.4.14.1. Overview
11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.14.3. Thailand Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
11.4.14.4. Thailand Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.4.14.5. Thailand Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.4.14.6. Thailand Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.4.15. Philippines
11.4.15.1. Overview
11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.15.3. Philippines Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
11.4.15.4. Philippines Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.4.15.5. Philippines Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.4.15.6. Philippines Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.4.16. Rest of APAC
11.4.16.1. Overview
11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.16.3. Rest of APAC Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
11.4.16.4. Rest of APAC Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.4.16.5. Rest of APAC Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.4.16.6. Rest of APAC Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.5. Latin America (LATAM)
11.5.1. Overview
11.5.2. mRNA Vaccines And Therapeutics Key Manufacturers in Latin America
11.5.3. LATAM Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
11.5.4. LATAMMarket Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
11.5.5. LATAMMarket Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.5.6. LATAMMarket Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.5.7. LATAMMarket Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.5.8. Brazil
11.5.8.1. Overview
11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.5.8.3. Brazil Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
11.5.8.4. Brazil Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.5.8.5. Brazil Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.5.8.6. Brazil Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.5.9. Mexico
11.5.9.1. Overview
11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.5.9.3. Mexico Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
11.5.9.4. Mexico Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.5.9.5. Mexico Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.5.9.6. Mexico Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.5.10. Argentina
11.5.10.1. Overview
11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.5.10.3. Argentina Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
11.5.10.4. Argentina Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.5.10.5. Argentina Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.5.10.6. Argentina Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.5.11. Colombia
11.5.11.1. Overview
11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.5.11.3. Colombia Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
11.5.11.4. Colombia Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.5.11.5. Colombia Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.5.11.6. Colombia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.5.12. Rest of LATAM
11.5.12.1. Overview
11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.5.12.3. Rest of LATAM Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
11.5.12.4. Rest of LATAM Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.5.12.5. Rest of LATAM Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.5.12.6. Rest of LATAM Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.6. Middle East and Africa (MEA)
11.6.1. Overview
11.6.2. mRNA Vaccines And Therapeutics Key Manufacturers in Middle East and Africa
11.6.3. MEA Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
11.6.4. MEA Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
11.6.5. MEA Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.6.6. MEA Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.6.7. MEA Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.6.8. Saudi Arabia
11.6.8.1. Overview
11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.8.3. Saudi Arabia Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
11.6.8.4. Saudi Arabia Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.6.8.5. Saudi Arabia Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.6.8.6. Saudi Arabia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.6.9. United Arab Emirates
11.6.9.1. Overview
11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.9.3. United Arab Emirates Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
11.6.9.4. United Arab Emirates Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.6.9.5. United Arab Emirates Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.6.9.6. United Arab Emirates Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.6.10. Israel
11.6.10.1. Overview
11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.10.3. Israel Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
11.6.10.4. Israel Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.6.10.5. Israel Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.6.10.6. Israel Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.6.11. Turkey
11.6.11.1. Overview
11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.11.3. Turkey Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
11.6.11.4. Turkey Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.6.11.5. Turkey Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.6.11.6. Turkey Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.6.12. Algeria
11.6.12.1. Overview
11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.12.3. Algeria Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
11.6.12.4. Algeria Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.6.12.5. Algeria Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.6.12.6. Algeria Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.6.13. Egypt
11.6.13.1. Overview
11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.13.3. Egypt Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
11.6.13.4. Egypt Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.6.13.5. Egypt Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.6.13.6. Egypt Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11.6.14. Rest of MEA
11.6.14.1. Overview
11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.14.3. Rest of MEA Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
11.6.14.4. Rest of MEA Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.6.14.5. Rest of MEA Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
11.6.14.6. Rest of MEA Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
12. Key Vendor Analysis- mRNA Vaccines And Therapeutics Industry
12.1. Competitive Benchmarking
12.1.1. Competitive Dashboard
12.1.2. Competitive Positioning
12.2. Company Profiles
12.2.1. AstraZeneca
12.2.2. Arcturus Therapeutics
12.2.3. BioNTech SE
12.2.4. CureVac N.V.
12.2.5. Daiichi Sankyo
12.2.6. Ethris
12.2.7. GlaxoSmithKline
12.2.8. Innovac Therapeutics
12.2.9. Kernal Biologics
12.2.10. Pantherna Therapeutics
12.2.11. pHion Therapeutics
12.2.12. Pfizer Inc.
12.2.13. Recode Therapeutics
12.2.14. Rejuvenation Technologies
12.2.15. RNAimmune
12.2.16. Strand Therapeutics
12.2.17. Moderna, Inc.
12.2.18. Walvax
12.2.19. Ziphius Vaccines
12.2.20. Others
13. 360 Degree AnalystView
14. Appendix
14.1. Research Methodology
14.2. References
14.3. Abbreviations
14.4. Disclaimer
14.5. Contact Us
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL MRNA VACCINES AND THERAPEUTICS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- AstraZeneca
- Arcturus Therapeutics
- BioNTech SE
- CureVac N.V.
- Daiichi Sankyo
- Ethris
- GlaxoSmithKline
- Innovac Therapeutics
- Kernal Biologics
- Pantherna Therapeutics
- pHion Therapeutics
- Pfizer Inc.
- Recode Therapeutics
- Rejuvenation Technologies
- RNAimmune
- Strand Therapeutics
- Moderna, Inc.
- Walvax
- Ziphius Vaccines
- Others
GLOBALMRNA VACCINES AND THERAPEUTICS MARKET, BY TREATMENT TYPE - MARKET ANALYSIS, 2020 - 2033
- Cell Therapy
- Gene Therapy
- Monoclonal Antibody
- Other
GLOBAL MRNA VACCINES AND THERAPEUTICS MARKET, BY TYPE - MARKET ANALYSIS, 2020 - 2033
- Conventional Non-Amplifying mRNA-Based Vaccines
- Self-Amplifying mRNA-based Vaccines
GLOBAL MRNA VACCINES AND THERAPEUTICS MARKET, BY APPLICATION- MARKET ANALYSIS, 2020 - 2033
- Autoimmune Diseases
- Cancer
- Infectious Diseases
- Others
GLOBAL MRNA VACCINES AND THERAPEUTICS MARKET, BY END USER- MARKET ANALYSIS, 2020 - 2033
- Clinics
- Hospitals
- Research Laboratories and Organizations
- Others
GLOBAL MRNA VACCINES AND THERAPEUTICS MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
Related Reports
Credibility and Certifications
Trusted Insights, Certified Excellence! Coherent Market Insights is a certified data advisory and business consulting firm recognized by global institutes.
ISO 9001:2015
ESOMAR Corporate
GDPR Compliance
D-U-N-S Registered
BBB Accreditation
MRS
